288 related articles for article (PubMed ID: 21480207)
1. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
Mesa RA; Kantarjian H; Tefferi A; Dueck A; Levy R; Vaddi K; Erickson-Viitanen S; Thomas DA; Cortes J; Borthakur G; Pardanani AD; Estrov Z; Verstovsek S
Cancer; 2011 Nov; 117(21):4869-4877. PubMed ID: 21480207
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
[TBL] [Abstract][Full Text] [Related]
4. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ruxolitinib for myelofibrosis.
Santos FP; Verstovsek S
Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic management of myelofibrosis.
Leung M; Highsmith K; Rexwinkle A
J Oncol Pharm Pract; 2017 Dec; 23(8):591-601. PubMed ID: 27672139
[TBL] [Abstract][Full Text] [Related]
11. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.
Harrison CN; Mesa RA; Kiladjian JJ; Al-Ali HK; Gisslinger H; Knoops L; Squier M; Sirulnik A; Mendelson E; Zhou X; Copley-Merriman C; Hunter DS; Levy RS; Cervantes F; Passamonti F; Barbui T; Barosi G; Vannucchi AM
Br J Haematol; 2013 Jul; 162(2):229-39. PubMed ID: 23672349
[TBL] [Abstract][Full Text] [Related]
14. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
[TBL] [Abstract][Full Text] [Related]
16. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
Wilkins BS; Radia D; Woodley C; Farhi SE; Keohane C; Harrison CN
Haematologica; 2013 Dec; 98(12):1872-6. PubMed ID: 24056820
[TBL] [Abstract][Full Text] [Related]
17. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
18. Management of myelofibrosis: JAK inhibition and beyond.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
[TBL] [Abstract][Full Text] [Related]
19. Janus activated kinase inhibition in myelofibrosis.
Malhotra H
Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
[TBL] [Abstract][Full Text] [Related]
20. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]